| fullrecord |
[{"key": "dc.contributor.advisor", "value": "Hulmi, Juha", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Hentil\u00e4, Jaakko", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Tulonen, Mervi", "language": "", "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2018-12-19T09:39:56Z", "language": null, "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2018-12-19T09:39:56Z", "language": null, "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2018", "language": "", "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/60679", "language": null, "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Johdanto. Sy\u00f6p\u00e4 ja siihen liittyv\u00e4 kakeksia ovat maailman johtavia kuolinsyit\u00e4. Kakeksiassa paino \nlaskee, lihakset surkastuvat ja yleiskunto huononee. Toisinaan kunnon heikentyminen est\u00e4\u00e4 sy\u00f6p\u00e4hoitojen jatkamisen. Kakeksiaa voidaan mahdollisesti hoitaa inhiboimalla lihasmassan negatiivisia \ns\u00e4\u00e4telij\u00f6it\u00e4, myostatiinia ja aktiviinia. Sy\u00f6p\u00e4 saa aikaan my\u00f6s immuunipuolustuksen akuutin vaiheen \nvasteen. T\u00e4m\u00e4 aiheuttaa positiivisten akuutin vaiheen proteiinien lis\u00e4\u00e4ntyneen tuotannon maksassa \nja mahdollisesti my\u00f6s lihaksissa. T\u00e4m\u00e4n tutkimuksen tarkoituksena oli selvitt\u00e4\u00e4, tuottaako luurankolihas akuutin vaiheen proteiineja kokeellisessa C26-sy\u00f6v\u00e4ss\u00e4 hiirill\u00e4, koska t\u00e4m\u00e4 oli se ilmi\u00f6, joka \nl\u00f6ytyi proteomiikka-analyysin avulla t\u00e4m\u00e4n tutkimuksen ensimm\u00e4isess\u00e4 vaiheessa.\nMenetelm\u00e4t. Tutkimuksessa k\u00e4ytettiin BALB/c -hiiri\u00e4, joille injektoitiin paksusuolen sy\u00f6v\u00e4st\u00e4 eristettyj\u00e4 tyypin 26 -sy\u00f6p\u00e4soluja (C26). Hiiret jaettiin sattumanvaraisesti nelj\u00e4\u00e4n ryhm\u00e4\u00e4n. Ryhm\u00e4t olivat: terve kontrolliryhm\u00e4 (CTRL, N = 9), sy\u00f6p\u00e4ryhm\u00e4 lumel\u00e4\u00e4kehoidolla (C26 + PBS, N = 9), sy\u00f6p\u00e4ryhm\u00e4 sACVR2B-Fc -hoidolla ennen sy\u00f6p\u00e4solujen injektointia (C26 + ACVR b, N = 7) ja sy\u00f6p\u00e4ryhm\u00e4 sACVR2B-Fc -hoidolla koko intervention ajan (C26 + ACVR c, N = 8). Hiiret lopetettiin 11 \nvuorokautta sy\u00f6p\u00e4soluinjektion j\u00e4lkeen ja lihakset irrotettiin ja n\u00e4ytteet homogenoitiin. T\u00e4m\u00e4n j\u00e4lkeen lihasn\u00e4ytteille tehtiin nano-LC-HD-MSE -analyysi. N\u00e4ist\u00e4 proteiineista tarkasti tunnistetut ja \neniten muuttuneet (kaksi uniikkia peptidi\u00e4 tunnistettiin, FDR < 0,05 ja FC |1.5|) analysoitiin viel\u00e4 \nIngenuity pathway -analyysin avulla tarkemmin. Muutoksia proteiinipitoisuuksissa haarukoitiin pro-teomiikkatekniikan avulla, mink\u00e4 j\u00e4lkeen tulokset validoitiin Western blottauksella ja/tai RT \nqPCR:ll\u00e4.\nTulokset. Proteomiikka- ja Ingenuity pathway -analyyseist\u00e4 nousivat esiin akuutti immuunivaste ja \nakuutin vaiheen proteiinit. Yksitt\u00e4isist\u00e4 akuutin immuunivasteen proteiineista serpiini A3N, STAT3 \nja p-STAT3 m\u00e4\u00e4r\u00e4t nousivat tilastollisesti eritt\u00e4in merkitsev\u00e4sti (p <0.001) lihaksessa sy\u00f6p\u00e4ryhmiss\u00e4 \nverrattuna kontrolliryhm\u00e4\u00e4n. Lis\u00e4ksi serpiini A3N, fibrinogeeni ja SAA (serum amyloid A -proteiini)\nl\u00e4hetti-RNA olivat nousseet lihaksessa tilastollisesti merkitsev\u00e4sti (p <0.05) sy\u00f6p\u00e4ryhmiss\u00e4 verrattuna kontrolliryhm\u00e4\u00e4n. Lis\u00e4ksi sy\u00f6p\u00e4ryhm\u00e4ll\u00e4 fyysinen aktiivisuus laski ja lihakset (TA ja GM) surkastuivat koejakson aikana verrattuna kontrolliryhm\u00e4\u00e4n. Aktiviinireseptorihoidolla ei ollut tilastollisesti merkitsev\u00e4\u00e4 vaikutusta akuutin immuunivasteen proteiinien muutoksiin sy\u00f6p\u00e4ryhm\u00e4\u00e4n verrattuna.\nJohtop\u00e4\u00e4t\u00f6kset. Kokeellinen C26-sy\u00f6p\u00e4 ja siihen liittyv\u00e4 kakeksia aiheuttivat t\u00e4ss\u00e4 tutkimuksessa \nluustolihasten surkastumista, kehon painon laskua ja v\u00e4hensiv\u00e4t fyysist\u00e4 aktiivisuutta. Kakeksia siis \ntoteutui 11 vuorokauden sy\u00f6p\u00e4jaksolla C26 -sy\u00f6v\u00e4ss\u00e4 hiirill\u00e4. Akuutin immuunivasteen proteiinien \n(APP) konsentraation nousu ja n\u00e4iden proteiinien l\u00e4hetti-RNA:n m\u00e4\u00e4r\u00e4n lis\u00e4\u00e4ntyminen C26-sy\u00f6v\u00e4st\u00e4 \nk\u00e4rsivien hiirten luurankolihaksessa vahvisti k\u00e4sityksen siit\u00e4, ett\u00e4 lihas voi toimia immuunielimen\u00e4 \nja voi tuottaa akuutin immuunivasteen proteiineja.", "language": "fi", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Introduction. Cancer and related cachexia are the world's leading causes of death. The ca-\nchexia means cancer related weight loss, muscle wasting and general condition weakened. \nSometimes a deterioration of the condition prevents the continuation of cancer treatments. \nCachexia may be treated by inhibiting muscle mass negative regulators, myostatin and activins. Cancer also causes an acute phase response to immune defense. This causes a positive \nacute phase of increased protein production in the liver and muscles. The muscle thus may \nacts as an immune organ. The purpose of this study was to find out if skeletal muscle produces acute phase proteins in experimental C26-cancer because this was the phenomenon \nfound by proteomics analysis at the first stage of the study.\nMethods. BALB/c mice and Colon-26 carcinoma (C26) cancer were used in the study.\nThe mice were randomized to four group. Groups are: healthy control group (CTRL, n = \n9), placebo treatment group (C26 + PBS, n = 9), sACVR2B-Fc treatment only before C26 \ninoculation group (C26 + ACVR c, n = 7) and both before and after C26 inoculation \ntreated group (ACVR b, n = 8). Muscles were collected on day 11 after C26 cell injection, \nlysed and subjected to nano\u2010LC\u2010HD\u2010MSE analysis. Proteins with \u2265 2 unique peptides, \nFDR < 0.05 and FC > |1.5| were analysed and further characterized using Ingenuity Pathway Analysis (IPA) software. Acute phase proteins were determined by Western blot protein analysis and/or RT-qPCR mRNA analysis.\nResults. Proteomics and Ingenuity pathway analysis arose in acute immune response and \nacute phase proteins. From individual acute response proteins serpin A3N and phosphorylated as well as total STAT3 had statistically significantly increased (p <0.001) in cancer\ngroups compared to the control group. In addition serpin A3N, fibrinogen and SAA messenger RNA had statistically significantly increased (p <0.05) in cancer groups compared \nto control group. In addition, the physical activity decreases in cancer group and the muscles (TA and GM) got smaller during the experiment compared to control group.\nConclusions. In this study, experimental C26 cancer and related cachexia expressed in the \nskeletal muscle wasting, decreased body weight, and decreased physical activity. This con-\nfirm that cachexia realized during the 11-day trial period C26 carcinoma in mice. The in-\ncrease in the concentration of APP proteins and the increase in the number of messengers \nRNAs of these proteins confirmed the understanding that muscles could act as an immune \norgan, producing APP proteins.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by Paivi Vuorio (paelvuor@jyu.fi) on 2018-12-19T09:39:56Z\nNo. of bitstreams: 0", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2018-12-19T09:39:56Z (GMT). No. of bitstreams: 0\n Previous issue date: 2018", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "64", "language": "", "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.format.mimetype", "value": "application/pdf", "language": null, "element": "format", "qualifier": "mimetype", "schema": "dc"}, {"key": "dc.language.iso", "value": "fin", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.subject.other", "value": "akuutti immuunivaste", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "sACVR2B-Fc", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "sy\u00f6v\u00e4n kakeksia", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "akuutin vaiheen proteiini", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.title", "value": "Immuunipuolustuksen akuutin vaiheen vaste kokeellisessa sy\u00f6v\u00e4ss\u00e4 ja luustolihaksen toiminta immuunielimen\u00e4", "language": "", "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-201812195215", "language": "", "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Liikuntatieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sport and Health Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Liikunta- ja terveystieteet", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Sport and Health Sciences", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Liikuntafysiologia", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Exercise Physiology", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "yvv.contractresearch.funding", "value": "0", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "openAccess", "language": null, "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "5011", "language": "", "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "sy\u00f6p\u00e4taudit", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "immuunivaste", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.format.content", "value": "fulltext", "language": null, "element": "format", "qualifier": "content", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}, {"key": "dc.type.okm", "value": "G2", "language": null, "element": "type", "qualifier": "okm", "schema": "dc"}]
|